Premium
Cyclin‐Dependent kinase 5 targeting prevents β‐Amyloid aggregation involving glycogen synthase kinase 3β and phosphatases
Author(s) -
CastroAlvarez John Fredy,
UribeArias Alejandro,
CardonaGómez Gloria Patricia
Publication year - 2015
Publication title -
journal of neuroscience research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.72
H-Index - 160
eISSN - 1097-4547
pISSN - 0360-4012
DOI - 10.1002/jnr.23576
Subject(s) - cyclin dependent kinase 5 , gsk 3 , glycogen synthase , microbiology and biotechnology , kinase , chemistry , gene knockdown , neurodegeneration , gsk3b , phosphorylation , activator (genetics) , biology , biochemistry , protein kinase a , cyclin dependent kinase 2 , medicine , apoptosis , disease , gene
Inappropriate activation of cyclin‐dependent kinase 5 (CDK5) resulting from proteolytic release of the activator fragment p25 from the membrane contributes to the formation of neurofibrillary tangles, β‐amyloid (βA) aggregation, and chronic neurodegeneration. At 18 months of age, 3× Tg‐AD mice were sacrificed after either 3 weeks (short term) or 1 year (long term) of CDK5 knockdown. In short‐term‐treated animals, CDK5 knockdown reversed βA aggregation in the hippocampi via inhibitory phosphorylation of glycogen synthase kinase 3β Ser9 and activation of phosphatase PP2A. In long‐term‐treated animals, CDK5 knockdown induced a persistent reduction in CDK5 and prevented βA aggregation, but the effect on amyloid precursor protein processing was reduced, suggesting that yearly booster therapy would be required. These findings further validate CDK5 as a target for preventing or blocking amyloidosis in older transgenic mice. © 2015 Wiley Periodicals, Inc.